Merck & Co., Inc. and BioImage A/S sign licensing deal on Redistribution® Technology
BioImage A/S, Denmark announced that it has signed a licensing agreement with Merck & Co, Inc. granting Merck the freedom to use BioImage's Redistribution® technology in its drug discovery research. Financial terms were not disclosed.
The Redistribution® patent portfolio covers a broad range of methods aimed at studying intracellular signalling events. The Redistribution® technology enables high throughput screening on a number of drug discovery live cell screening applications, such as protein translocations, receptor internalizations, protein trafficking, secretions, etc. BioImage is presently out licensing the portfolio to a number of leading companies within the life science industry.
"We are delighted and proud to have a world class pharmaceutical company like Merck license our patent portfolio", said Dr. Patrik Dahlén, CEO of BioImage. "By using the Redistribution® technology, researchers can track proteins in living cells and screen for compounds that affect specific cellular signalling pathways. This improves the biological relevance of drug screening and helps increase the speed and accuracy of drug discovery and development. At BioImage, we have developed an extensive experience in the area of protein translocation assays and pathway screening."
Other news from the department business & finance
